Incidence and treatment of cancer in transplant recipients.
Solid organ transplantation has been an accepted mode of therapy for the treatment of end-stage organ diseases for many years. Recipients' survival, however, has been hindered by organ rejection and the comorbid diseases that develop as a result of immunosuppresive therapy. In particular, organ transplant recipients have an increased risk of developing cancer de novo after transplantation. Prevalence ranges from 4 to 18% with an average incidence of 6%. Data submitted to the Cincinnati transplant tumor registry have revealed that cancers prevalent in the general population exhibited no increase in rate and may even show a slight decline in the transplant population. Length of survival after transplantation is associated with the likelihood of having cancer; the longer the recipient survives, the greater the chance. The actuarial risk among 124 cardiac transplant recipients was 2.7 +/- 1.9% at 1 year and 25.6 +/- 11% at 5 years. This article will review the current literature on the incidence and treatment of cancer in solid organ transplant recipients.
Flattery
M P
MP
Virginia Commonwealth University, Medical College of Virginia, Richmond, USA.
D000206:Actuarial Analysis; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D015994:Incidence; D009369:Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D009720:Nurse Clinicians; D015995:Prevalence; D012042:Registries; D012307:Risk Factors; D016019:Survival Analysis; D014180:Transplantation / Q000009:adverse effects*; D014481:United States / Q000453:epidemiology